Terms: = Liver cancer AND NOTCH1, TAN1, P46531, 4851, ENSG00000148400, hN1 AND Diagnosis
10 results:
1. Targeted liver ultrasound performed by an expert is the pivotal imaging examination for low phospholipid-associated cholelithiasis.
Su S; Trinh A; Metz AJ; Speer T; Simkin P; Buchanan D; Boussioutas A; Gibson R
Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):327-332. PubMed ID: 36708304
[TBL] [Abstract] [Full Text] [Related]
2. Hematological and neurological expressed 1 (hn1) activates c-Myc signaling by inhibiting ubiquitin-mediated proteasomal degradation of c-Myc in hepatocellular carcinoma.
Feng J; Liu Y; Fang T; Zhu J; Wang G; Li J
Cell Biol Int; 2023 Mar; 47(3):560-572. PubMed ID: 36403281
[TBL] [Abstract] [Full Text] [Related]
3. Gastric carcinosarcoma with FGFR2 amplification under long-term control with pazopanib: a case report and literature review.
Hayashi H; Makiyama A; Okumura N; Yasufuku I; Saigo C; Takeuchi T; Miyazaki T; Tanaka Y; Matsuhashi N; Murase K; Takahashi T; Futamura M; Yoshida K
BMC Gastroenterol; 2022 Jul; 22(1):360. PubMed ID: 35902814
[TBL] [Abstract] [Full Text] [Related]
4. Data mining of key genes expression in hepatocellular carcinoma: novel potential biomarkers of diagnosis prognosis or progression.
Cabiati M; Gaggini M; De Simone P; Del Ry S
Clin Exp Metastasis; 2022 Aug; 39(4):589-602. PubMed ID: 35429302
[TBL] [Abstract] [Full Text] [Related]
5. hn1 as a diagnostic and prognostic biomarker for liver cancer.
Liu Z; Yang D; Li Y; Jiao Y; Lv G
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32700728
[TBL] [Abstract] [Full Text] [Related]
6. MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the notch1 signaling pathway.
Li JH; Zhu XX; Li FX; Huang CS; Huang XT; Wang JQ; Gao ZX; Li SJ; Xu QC; Zhao W; Yin XY
J Exp Clin Cancer Res; 2019 Nov; 38(1):476. PubMed ID: 31775892
[TBL] [Abstract] [Full Text] [Related]
7. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract] [Full Text] [Related]
8. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up.
Cabiati M; Gaggini M; Cesare MM; Caselli C; De Simone P; Filipponi F; Basta G; Gastaldelli A; Del Ry S
Cytokine; 2017 Nov; 99():59-65. PubMed ID: 28711012
[TBL] [Abstract] [Full Text] [Related]
9. Activating notch1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and liver Metastasis, and Potential Responsiveness to notch1 Inhibitors.
Ferrarotto R; Mitani Y; Diao L; Guijarro I; Wang J; Zweidler-McKay P; Bell D; William WN; Glisson BS; Wick MJ; Kapoun AM; Patnaik A; Eckhardt G; Munster P; Faoro L; Dupont J; Lee JJ; Futreal A; El-Naggar AK; Heymach JV
J Clin Oncol; 2017 Jan; 35(3):352-360. PubMed ID: 27870570
[TBL] [Abstract] [Full Text] [Related]
10. Three-dimensional contrast-enhanced ultrasound of the liver: experience of 92 cases.
Xu HX; Lu MD; Xie XH; Xie XY; Xu ZF; Chen LD; Liu GJ; Liang JY; Lin MX; Wang Z; Huang B
Ultrasonics; 2009 Mar; 49(3):377-85. PubMed ID: 19041996
[TBL] [Abstract] [Full Text] [Related]
